SecBot SecBot
S-3 ·Filed Nov 9, 2026

TTRX

Turn Therapeutics Inc.
BEARISH
Impact 6/10
Horizonweeks Processed7d 16h ago SEC0001213900-26-117232
Shelf registration (potential dilution)
Actionable Insight ▼ Bearish

Monitor the pace of ATM draws and subsequent filings for actual share sales. The company's cash runway into Q3 2027 suggests near-term dilution is likely to fund ongoing clinical trials. Watch for Phase 2b topline results for GX-03 in Q1 2027 as a potential catalyst.

DirectionBearish
Confidencehigh
Horizonweeks

GX-03

▲ Bullish Named in this S-3
Impact
Phase
Phase 2
Time to market
~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
Next catalyst
None dated

What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$9.79
T+0 close · Nov 9, 2026 · via day close
Latest settled
−12.67%
T+5 · $8.55
Vs SPY
−10.97%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $9.79entry
  2. T+1 · 7d ago +1.33%α +1.70% · $9.92
  3. T+5 · 18h ago −12.67%α −10.97% · $8.55
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Turn Therapeutics filed a universal shelf registration statement on Form S-3 to offer up to $150M in securities, including a $50M at-the-market (ATM) equity program with TD Cowen. The company is a pre-revenue clinical-stage biotech with a net loss of $6.2M in Q3 2026 and only $10.4M in cash, making this a capital raise to fund operations and clinical trials into Q3 2027. The filing signals significant potential dilution for existing shareholders.

Key Financial Metrics

Offering Size
$50.0M

Key Facts

  • Shelf registration for up to $150M in securities, including a $50M ATM with TD Cowen.
  • Company reported a net loss of $6.2M in Q3 2026, wider than $1.9M loss in Q3 2025.
  • Cash and cash equivalents of $10.4M as of September 30, 2026, funding operations into Q3 2027.
  • Pre-revenue clinical-stage biotech with no approved products.
  • 10 offering/registration filings in the last 24 months, indicating frequent capital needs.
  • Market cap of $273M; $50M ATM represents ~18% of market cap in potential dilution.
  • Proceeds used for general corporate purposes including R&D, clinical development, and working capital.

Financial Impact

Up to $150M in potential securities issuance, with $50M ATM representing ~18% of current market cap; net loss of $6.2M in Q3 2026 vs $1.9M in Q3 2025.

dilutioncash runwayshare count

Risk Factors

  • Significant dilution from potential $50M ATM issuance (up to ~5.3M shares at $9.48).
  • Pre-revenue status with widening losses and reliance on capital markets for funding.
  • Frequent past offerings suggest ongoing capital needs; 10 filings in 24 months.
  • Clinical-stage risk: GX-03 Phase 2b results not expected until Q1 2027.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001213900-26-117232
Document: ea030998001ex4-5.htm0001213900-26-117232
Document: ea030998001ex1-2.htm0001213900-26-117232

Track record

19 reports on TTRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $9.92 Now $8.55 −13.81% settles Feb 8
  3. Nov 9, 20267d ago S-3 Bearish 6/10 Viewing Entry $9.79 Now $8.55 +12.67% settles Feb 5
  4. Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
  5. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $9.79 Now $8.55 −12.67% settles Feb 5
  6. Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
  7. Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
  8. Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
  9. Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
  10. Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026